HbA1c Reduction with Farxiga (Dapagliflozin)
Farxiga lowers HbA1c by approximately 0.5% to 1.0% when used as monotherapy or add-on therapy in adults with type 2 diabetes. 1, 2
Magnitude of HbA1c Reduction by Clinical Context
Monotherapy
- HbA1c reduction: 0.7-0.9% compared to placebo at 24 weeks 3
- In the pivotal monotherapy trial, Farxiga 10 mg reduced HbA1c by 0.9% from a baseline of 8.0%, with 50.8% of patients achieving HbA1c <7% 3
Add-on to Metformin
- HbA1c reduction: 0.5-0.8% compared to placebo 3
- At 24 weeks, Farxiga 10 mg added to metformin reduced HbA1c by 0.8% from baseline of 8.1%, with 40.6% achieving target HbA1c <7% 3
Initial Combination with Metformin
- HbA1c reduction: 2.0% when started together with metformin in treatment-naive patients 3
- This represents a 0.5% greater reduction than metformin alone and 0.5% greater than dapagliflozin alone 3
Add-on to Insulin (with or without other agents)
Combination with GLP-1 Receptor Agonist
- HbA1c reduction: 1.77% when combined with exenatide extended-release plus metformin 3
- This was significantly greater than dapagliflozin alone (1.32%) or exenatide alone (1.42%) 4
- The combination reduced HbA1c by 2 percentage points more than either medication alone 4
Moderate Renal Impairment (eGFR 45-60 mL/min/1.73 m²)
- HbA1c reduction: 0.3% compared to placebo at 24 weeks 3
- The glucose-lowering efficacy is reduced as kidney function declines, though cardiovascular and renal benefits are preserved 5
Key Clinical Considerations
Baseline HbA1c matters: Patients with higher baseline HbA1c (>9%) tend to achieve greater absolute reductions. In trials with baseline HbA1c of 9.0-9.2%, reductions of 1.2-2.1% were observed 3.
Duration of diabetes influences response: Shorter diabetes duration is significantly associated with better glycemic response 6. Patients with longer diabetes duration may experience smaller HbA1c reductions.
Early response predicts long-term benefit: Patients who show favorable HbA1c reduction early (within the first few months) are more likely to maintain good glycemic control long-term 6.
Renal function affects efficacy: The glucose-lowering effect is blunted with reduced kidney function 5, 7. However, dapagliflozin should still be used for its cardiovascular and renal protective benefits even when eGFR is 25-45 mL/min/1.73 m² 5.
Common Pitfalls
Do not discontinue dapagliflozin solely because HbA1c reduction appears modest in patients with moderate renal impairment—the medication provides critical cardiovascular death reduction and heart failure hospitalization benefits independent of glucose lowering 5, 8, 9.
Do not expect the same degree of HbA1c lowering in patients with long-standing diabetes (>10 years) compared to those with recent diagnosis 6.
The HbA1c-lowering effect may be underestimated in SGLT2i users due to alterations in the hemoglobin glycation index—consider using continuous glucose monitoring metrics (GMI) or glycated albumin for more accurate assessment 10.